Dr Ellis is an Associate Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University. He is also a staff medical oncologist at the Juravinski Cancer Centre (JCC). He obtained his medical degree at the University of Sydney. He is trained in internal medicine and medical oncology, and is a Fellow of the Royal Australasian College of Physicians and the Royal College of Physicians and Surgeons of Canada. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney. Dr Ellis moved to Canada in October, 2000. He is the acting Head of Medical Oncology, an Executive Member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group. Dr Ellis has a research interest in the role of the consumer in decision making, and is an investigator in several studies in this area.
Dawe DE, Greenspoon J, Ellis PM. Brain metastases in non small cell lung cancer. Clinical Lung Cancer 2014; 15(4): 249-257
Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA. Brief report: NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive stage small cell lung cancer (ES SCLC). Journal of Thoracic Oncology 2014; 9(3):410-413
Ellis PM, Verma S, Sandeep S, Younus J, and Leighl NB. Challenges to implementation of an epidermal growth factor receptor (EGFR) testing strategy for no-small cell lung cancer (NSCLC) in a publicly funded healthcare system. Journal of Thoracic Oncology. 2013; 8(9): 1136-41
Ellis PM, N Blais, D Soulieres, DN Ionescu, M Kashyap, G Liu, B Melosky, T Reiman, P Romeo, FA Shepherd, MS Tsao, NB Leighl. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of Non-Small Cell Lung Carcinoma (NSCLC). Journal of Thoracic Oncology 2011; 6(8): 1379-1391